Sort   by:  
 Page size 
UnknownRandomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Not available
S-EPMC5089161 | biostudies-literature
UnknownPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Not available
S-EPMC5321045 | biostudies-literature
UnknownUse of sediment dwelling bivalves to biomonitor plastic particle pollution in intertidal regions; A review and study.
Not available
S-EPMC7244099 | biostudies-literature
UnknownSafety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Not available
S-EPMC5657013 | biostudies-literature
UnknownCheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Not available
S-EPMC6161834 | biostudies-literature
UnknownRandomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Not available
S-EPMC4878105 | biostudies-literature
UnknownIndividual and team profiling to support theory of mind in artificial social intelligence.
Not available
S-EPMC11144695 | biostudies-literature
UnknownArtificial social intelligence in teamwork: how team traits influence human-AI dynamics in complex tasks.
Not available
S-EPMC11873349 | biostudies-literature
UnknownGB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
Not available
S-EPMC8404448 | biostudies-literature
UnknownA Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma.
Not available
S-EPMC5344646 | biostudies-literature
Sort   by:  
 Page size